Hepatobiliary and Pancreatic Surgery Department I

Hepatobiliary and Pancreatic Surgery Department 1 at Peking University Cancer Hospital was established in 1996. It has 33 beds and 16 physicians, including ten senior physicians: three chief and seven associate chief physicians. Under the leadership of Huang Xinfu and Xing Baocai, it has combined surgical techniques with individualized, standardized multidisciplinary care for hepatobiliary and pancreatic tumors, aiming to extend survival, improve quality of life and relieve suffering. The hospital describes it as an influential Chinese liver tumor surgery center. The department reports more than 800 operations a year for colorectal cancer liver metastases and describes its clinical and research work as nationally leading. It routinely performs complex resections for large liver tumors, hilar and caudate-lobe tumors and recurrent lesions. Assessment includes preoperative three-dimensional reconstruction and individualized liver functional reserve measurement; intraoperative ultrasound and contrast-enhanced ultrasound guide malignant liver tumor resection. Techniques include resection with ablation for complex metastases, laparoscopic hepatectomy and anatomical segmentectomy. The hospital says it emphasizes safety through preoperative assessment, careful surgery and standardized postoperative care, reporting a low complication rate. The team collaborates with Chinese and international centers on hepatobiliary and pancreatic tumor research and multicenter trials. It reports progress in conversion and neoadjuvant treatment of colorectal liver metastases and liver cancer, molecular classification of hepatocellular carcinoma, prognostic models for colorectal liver metastases and next-generation-sequencing-guided individualized treatment. More than 200 papers have appeared in journals including Nature, Cancer Cell, Nature Communications and Annals of Surgery. The hospital says it was an early Chinese leader in multidisciplinary teams for colorectal liver metastases and promotes neoadjuvant and conversion treatment, reporting increased opportunities for potentially curative treatment. It plans to continue developing liver tumor surgery and individualized care.